Strain Name:

C57BL/6J-ApcMin/J

Stock Number:

002020

Availability:

Level 3

Description

Strain Information

Type Chemically Induced Mutation; Coisogenic; Mutant Strain;
Additional information on Genetically Engineered Mutant Mice.
Mating SystemInbred x Heterozygote         (Female x Male)
(C57BL/6J x Heterozygote)
Specieslaboratory mouse
GenerationN65 (20-DEC-06)
 
Donating Investigator Fang Jin,   Univ of California, San Francisco

Appearance
black
Related Genotype: a/a

Description
The C57BL/6J-ApcMin/J strain is highly susceptible to spontaneous intestinal adenoma formation. Homozygous mice are not viable. It was initially reported that one hundred percent of the C57BL/6J-ApcMin heterozygous mice raised on a high fat diet develop in excess of 30 adenomas throughout the intestinal tract and most die by 120 days of age. Heterozygotes also develop anemia. (Moser et al., 1990, Su et al., 1992). A small number of C57BL/6J-ApcMin heterozygous female mice develop mammary tumors. A subsequent publication indicates that this strain may carry a dominant modifier (Mom2) gene that reduces the number and incidence of polyp formation in C57BL/6J-ApcMin heterozygous mice (Silverman et al., 2002).

Development
The Min mutation was discovered in the progeny of a C57BL/6J male mutagenized by ethylnitrosourea. The founding (AKR x C57BL/6J)F1 female displayed circling behavior and was mated to a C57BL/6J male. Some progeny from this backcross developed adult onset anemia and intestinal adenomas. The circling behavior was determined to be a separate heritable trait and was eliminated through subsequent crosses to C57BL/6J. This strain was imported into The Jackson Laboratory in 1992.

Control Information

  Control
   Wild-type from the colony
   000664 C57BL/6J
 
  Considerations for Choosing Controls

Additional Web Information

Genetic Quality Control Annual Report
JAX® NOTES, Fall 1993; 455. The C57BL/6J-Min/+ Mouse.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms
Adenomatous Polyposis of the Colon; APC - Models with phenotypic similarity to human disease where etiologies involve orthologs.1
1 Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
View Mammalian Phenotype Terms

Mammalian Phenotype Terms
      assigned by genotype

ApcMin/Apc+

        involves: C57BL/6 * C57BL/6J
  • life span-post-weaning/aging
  • premature death (MGI Ref ID J:134087)
    • mice die at 169 days
  • digestive/alimentary phenotype
  • intestinal polyps (MGI Ref ID J:134087)
    • mice develop more and bigger polyps than in ApcMin Myctm1Jlc heterozygotes

The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.

ApcMin/Apc+

        involves: AKR/J * C57BL/6J
  • tumorigenesis
  • intestinal adenocarcinoma (MGI Ref ID J:10209)
    • locally invasive tumors seen in older animals but no metastasis
    • sometimes small areas of carcinomas in anemic animals only
  • intestinal adenoma (MGI Ref ID J:10209)
    • visible tumors of the large and small intestine
    • either polyploid, papillary or sessile adenomas
  • digestive/alimentary phenotype
  • melena (MGI Ref ID J:10209)
    • bloody feces
  • hematopoietic system phenotype
  • anemia (MGI Ref ID J:10209)
    • progressive adult onset anemia
  • decreased hematocrit (MGI Ref ID J:10209)
    • moribund animals with hematocrits around 10-20%
  • homeostasis/metabolism phenotype
  • hyperlipidemia (MGI Ref ID J:10209)

ApcMin/Apc+

        involves: C57BL/6J
  • life span-post-weaning/aging
  • premature death (MGI Ref ID J:94108)
    • heterozygotes begin to die at 7 months of age
  • tumorigenesis
  • intestinal adenoma (MGI Ref ID J:94108)
    • small and large adenomas are seen throughout the intestine with more lesions found in the ileum compared to Apctm1Cip heterozygotes
  • mammary adenocarcinoma (MGI Ref ID J:94108)
    • 12% of heterozygotes developed mammary adenocanthomas
  • digestive/alimentary phenotype
  • rectal prolapse (MGI Ref ID J:94108)
    • rectal prolapse is seen in 28% of surviving mutants at 7 months of age

ApcMin/Apc+

        B6.Cg-Brca2tm1Mbn ApcMin
  • growth/size phenotype
  • decreased body weight (MGI Ref ID J:67445)
    • body weight of mice at time of sacrifice differs significantly from Brca2-heterozygous and wild-type animals; mice show lower weight gain from start to end of experiment compared to other experimental genotypes
  • reproductive system phenotype
  • *normal* reproductive system phenotype (MGI Ref ID J:67445)
    • only observed in 1/9 ENU-treated males, similar to wild-type males (1/9)
    • abnormal mammary gland development (MGI Ref ID J:67445)
      • in ENU-treated mice, male mammary ducts are elongated and in most males have extended to the lymph node of the fourth mammary gland, whereas wild-type and Brca2-heterozygous males are born with a small mammary gland rudiment, which grows no further, and no nipple
      • no differences are observed in branching of female mammary glands among genotypes or wild-type females
    • abnormal ovarian follicle morphology (MGI Ref ID J:67445)
      • remaining follicles are degenerating in ENU-treated females
      • abnormal ovarian folliculogenesis (MGI Ref ID J:67445)
        • arrested follicular development is 6-fold more prevalent compared to ENU-treated Brca2-deficient mice
        • absent mature ovarian follicles (MGI Ref ID J:67445)
    • abnormal vagina epithelium morphology (MGI Ref ID J:67445)
      • reduced in thickness and lined with vacuolated cells indicative of anestrus in ENU-treated females
    • absent corpus luteum (MGI Ref ID J:67445)
      • absent in 26% of ENU-treated females
    • ovary atrophy (MGI Ref ID J:67445)
      • complete loss of follicles (ovarian atrophy) is observed in about 25% of ENU-treated mutants, whereas almost no incidence is observed in ENU-treated wild-type or Brca2-mutant females
    • uterus atrophy (MGI Ref ID J:67445)
      • observed in ENU-treated females displaying ovarian failure (atrophy); endometrium and myometrium appear immature
  • tumorigenesis
  • increased incidence of induced tumors (MGI Ref ID J:67445)
    • multiple intestinal tumors are observed in ENU-treated mice, similar to Apc-heterozygous mice
  • mammary gland tumor (MGI Ref ID J:67445)
    • by 65 days after ENU treatment, 100% of females develop mammary tumors with a multiplicity of 6.7 +/- 2.8
    • males develop tumors at a very low incidence and with a tumor multiplicity of 0.4 +/- 0.5, whereas no wild-type or Brca2-heterozygous males developed mammary tumors
    • tumors in male and female mice are adenoacanthomas, characterized by undifferentiated acini and tubules with centrally confined squamous cells and keratin; most tumors contain proportions of adenomatous and squamous cell types
    • tumors with predominantly squamous differentiation, moderate to marked inflammation in and around tumors is observed, with areas of fibrosis; in some cases, squamous component becomes cystic and is filled with keratinous debris
    • invasion or metastases into the mammary lymph nodes was not observed during time course of study
  • endocrine/exocrine gland phenotype
  • abnormal adrenal gland morphology (MGI Ref ID J:67445)
    • females exhibit some adrenal hyperplasia, while none is observed in males
  • abnormal mammary gland development (MGI Ref ID J:67445)
    • in ENU-treated mice, male mammary ducts are elongated and in most males have extended to the lymph node of the fourth mammary gland, whereas wild-type and Brca2-heterozygous males are born with a small mammary gland rudiment, which grows no further, and no nipple
    • no differences are observed in branching of female mammary glands among genotypes or wild-type females
  • abnormal ovarian follicle morphology (MGI Ref ID J:67445)
    • remaining follicles are degenerating in ENU-treated females
    • abnormal ovarian folliculogenesis (MGI Ref ID J:67445)
      • arrested follicular development is 6-fold more prevalent compared to ENU-treated Brca2-deficient mice
      • absent mature ovarian follicles (MGI Ref ID J:67445)
  • absent corpus luteum (MGI Ref ID J:67445)
    • absent in 26% of ENU-treated females
  • ovary atrophy (MGI Ref ID J:67445)
    • complete loss of follicles (ovarian atrophy) is observed in about 25% of ENU-treated mutants, whereas almost no incidence is observed in ENU-treated wild-type or Brca2-mutant females
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

ApcMin related

Cancer Research
Increased Tumor Incidence (Adenomas: intestinal adenomas)
Increased Tumor Incidence (Mammary Gland Tumors)

Mouse/Human Gene Homologs
adenomatosis polyposis coli

Genes & Alleles

Gene & Allele Information

Allele Symbol ApcMin
Allele Name multiple intestinal neoplasia
Allele Type Chemically induced (ENU)
Common Name(s) ApcΔ850; Apc-; Apcdelta850; Min; Min-;
Mutation Made By William Dove,   University of Wisconsin
Strain of OriginC57BL/6J
Gene Symbol and Name Apc, adenomatosis polyposis coli
Chromosome 18
Gene Common Name(s) AI047805; AU020952; AW124434; BTPS2; DP2; DP2.5; DP3; GS; Min; RATAPC; expressed sequence AI047805; expressed sequence AU020952; expressed sequence AW124434; multiple intestinal neoplasia;
General Note

ApcMin, multiple intestinal neoplasia, dominant. A fully penetrant dominant mutation induced in a C57BL/6J mouse by ethylnitrosourea was designated Min because heterozygotes develop multiple adenomas throughout the intestine (J:10209). It was subsequently shown to be a base substitution mutation in the Apc gene which creates a stop codon truncating the polypeptide (J:830).

ApcMin/+ mice develop an adult-onset progressive anemia characterized by a decreasing red cell countand an increasing proportion of reticulocytes, symptoms typical of anemia due to chronic blood loss. On the C57BL/6J genetic background on which ApcMin is maintained, this severe chronic anemia appears by 60 days of age and is probably the cause of death by 120 days of age in most affected mice. The anemia is presumably secondary to the development of multiple adenomas, which cause bleeding into the intestinal lumen (J:10209).

In older mice, the adenomas may progress into intestinal adenocarcinomas (J:10209). ApcMin/+ female mice are prone to develop mammary cancer, and their mammary glands are more sensitive to chemical carcinogens than those of wild-type females. Tissue transplants into wild-type hosts show that the propensity to develop mammary tumors is intrinsic to the ApcMin/+ mammary tissue. Focal alveolar hypoplasias also arise in long-term grafts of ApcMin mammary glands (J:15101). ApcMin/+ males are fertile but females are rarely healthy enough to maintain a pregnancy (J:10209). Homozygous mice for Min fail to survive beyond day 7 of gestation (J:27993).

In F1 hybrids, ApcMin/+ mice have a reduced number of tumors and may survive up to 300 days (J:10209). Tumors in C57BL/6J-ApcMin/+ mice are not invasive, but those in hybrid mice can become invasive. A single major modifying locus unlinked to Apc called Mom1 controls tumor number and growth rate (see Pla2g2a) (J:15703, J:37224). ApcMin/+ mutants provide a model for studying development of intestinal neoplasias.

Intestinal adenomas from ApcMin/+ homozygotes tend to lose the chromosome carrying the wild-type allele (J:21369). Treatment of the heterozygotes with ethylnitrosourea (ENU) tends to increase formation of neoplasms, presumably by eliminating the normal allele. The type of neoplasm initiated is dependent on the age at mutagen treatment (J:29099). Human tumors from APC mutant heterozygotes also tend to show inactivation of the normal APC allele (J:21856).

Mouse strains homozygous null for Trp53 and heterozygous ApcMin/+ show increased pancreatic neoplasia, with loss of the Apc+ allele in the neoplasms. These mice do not, however, develop increased intestinal malignancy (J:29664).

A targeted chain-termination mutation in the Apc gene causes development of multiple intestinal neoplasms in a manner similar to that of the spontaneous ApcMin mutation (J:20443). It was noted that intestinal polyps in mice heterozygous for another targeted truncation mutation lose the normal Apc gene, like those from heterozygotes for the spontaneous mutation (J:25200).

On the C57BL/6J genetic background on which ApcMin is maintained, severe chronic anemia appears by 60 days of age and is probably the cause of death by 120 days of age in most affected mice. The anemia is presumably secondary to the development of multiple adenomas, which cause bleeding into the intestinal lumen (J:10209). In older mice, the adenomas may progress into intestinal adenocarcinomas (J:10209). ApcMin/+ female mice are prone to develop mammary cancer, and their mammary glands are more sensitive to chemical carcinogens than those of wild-type females. ApcMin/+ males are fertile but females are rarely healthy enough to maintain a pregnancy (J:10209). Homozygotes fail to survive beyond day 7 of gestation (J:27993). In F1 hybrids ApcMin/+ mice have a reduced number of tumors and may survive up to 300 days (J:10209). Tumors in C57BL/6J-ApcMin/+ mice are not invasive, but those in hybrid mice can become invasive. A major modifying locus to Apc is Pla2g2a (formerly, Mom1), which controls tumor number and growth rate (J:15703, J:37224). Intestinal adenomas from ApcMin/+ homozygotes tend to lose the chromosome carrying the wild-type allele (J:21369). Human tumors from APC mutant heterozygotes also tend to show inactivation of the normal APC allele (J:21856).

Molecular Note A transversion point mutation that alters nucleotide 2549 from a T to an A. This converts codon 850 from one encoding a leucine to a stop codon. [MGI Ref ID J:830]

Genotyping

Genotyping Information

Genotyping Protocols

ApcMin, EP, vers. 4
ApcMin, STD PCR, vers. 3

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Moser AR; Pitot HC; Dove WF. 1990. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247(4940):322-4. [PubMed: 2296722]  [MGI Ref ID J:10209]

Su LK; Kinzler KW; Vogelstein B; Preisinger AC; Moser AR; Luongo C; Gould KA; Dove WF. 1992. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene [published erratum appears in Science 1992 May 22;256(5060):1114] Science 256(5057):668-70. [PubMed: 1350108]  [MGI Ref ID J:830]

Additional References

Andreassen A; Mollersen L; Vikse R; Steffensen IL; Mikalsen A; Paulsen JE; Alexander J. 2002. One dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) induces tumours in Min/+ mice by truncation mutations or LOH in the Apc gene. Mutat Res 517(1-2):157-66. [PubMed: 12034317]  [MGI Ref ID J:77184]

Andreassen A; Vikse R; Steffensen IL; Paulsen JE; Alexander J. 2001. Intestinal tumours induced by the food carcinogen 2-amino-1-methyl-6-phenylimidazo. Mutagenesis 16(4):309-15. [PubMed: 11420398]  [MGI Ref ID J:70642]

Barbour K W; Davis T; White A; Baumann H; Berger F G. 2001. Haptoglobin, inflammation, and tumorigenesis in the MIN mouse. Redox Rep 6(6):366-8. [PubMed: 11865977]  [MGI Ref ID J:75249]

Bennett LM; McAllister KA; Ward T; Malphurs J; Collins NK; Seely JC; Davis BJ; Wiseman RW. 2001. Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency. Toxicol Pathol 29(1):117-25. [PubMed: 11215675]  [MGI Ref ID J:67445]

Cooper AM; Magram J; Ferrante J; Orme IM. 1997. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. J Exp Med 186(1):39-45. [PubMed: 9206995]  [MGI Ref ID J:41494]

Davis CD; Zeng H; Finley JW. 2002. Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J Nutr 132(2):307-9. [PubMed: 11823596]  [MGI Ref ID J:74364]

De Giovanni C; Landuzzi L; Nicoletti G; Astolfi A; Croci S; Micaroni M; Nanni P; Lollini PL. 2004. Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. Int J Cancer 109(2):200-6. [PubMed: 14750170]  [MGI Ref ID J:88314]

Dinchuk JE; Focht RJ; Kelley JA; Henderson NL; Zolotarjova NI; Wynn R; Neff NT; Link J; Huber RM; Burn TC; Rupar MJ; Cunningham MR; Selling BH; Ma J; Stern AA; Hollis GF; Stein RB; Friedman PA. 2002. Absence of Post-translational Aspartyl beta -Hydroxylation of Epidermal Growth Factor Domains in Mice Leads to Developmental Defects and an Increased Incidence of Intestinal Neoplasia. J Biol Chem 277(15):12970-7. [PubMed: 11773073]  [MGI Ref ID J:75888]

Erik Paulsen J; Steffensen IL; Loberg EM; Husoy T; Namork E; Alexander J. 2001. Qualitative and Quantitative Relationship between Dysplastic Aberrant Crypt Foci and Tumorigenesis in the Min/+ Mouse Colon. Cancer Res 61(13):5010-5. [PubMed: 11431334]  [MGI Ref ID J:70170]

Ernest S; Christensen B; Gilfix BM; Mamer OA; Hosack A; Rodier M; Colmenares C; McGrath J; Bale A; Balling R; Sankoff D; Rosenblatt DS; Nadeau JH. 2002. Genetic and molecular control of folate-homocysteine metabolism in mutant mice. Mamm Genome 13(5):259-67. [PubMed: 12016514]  [MGI Ref ID J:76559]

Gould TD; Gray NA; Manji HK. 2003. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 48(1):49-53. [PubMed: 12770514]  [MGI Ref ID J:84200]

Greiner JW; Zeytin H; Anver MR; Schlom J. 2002. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62(23):6944-51. [PubMed: 12460911]  [MGI Ref ID J:80324]

Gupta RA; Wang D; Katkuri S; Wang H; Dey SK; DuBois RN. 2004. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10(3):245-7. [PubMed: 14758356]  [MGI Ref ID J:88127]

Gutierrez LS; Suckow M; Lawler J; Ploplis VA; Castellino FJ. 2003. Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 24(2):199-207. [PubMed: 12584168]  [MGI Ref ID J:79641]

Hansen-Petrik MB; McEntee MF; Jull B; Shi H; Zemel MB; Whelan J. 2002. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 62(2):403-8. [PubMed: 11809688]  [MGI Ref ID J:74005]

Hertervig E; Nilsson A; Nilbert M; Duan RD. 2003. Reduction in alkaline sphingomyelinase in colorectal tumorigenesis is not related to the APC gene mutation. Int J Colorectal Dis 18(4):309-13. [PubMed: 12774245]  [MGI Ref ID J:84197]

Hong KH; Bonventre JC; O'Leary E; Bonventre JV; Lander ES. 2001. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 98(7):3935-9. [PubMed: 11274413]  [MGI Ref ID J:68495]

Huang EH; Carter JJ; Whelan RL; Liu YH; Rosenberg JO; Rotterdam H; Schmidt AM; Stern DM; Forde KA. 2002. Colonoscopy in mice. Surg Endosc 16(1):22-4. [PubMed: 11961598]  [MGI Ref ID J:77864]

Huerta S; Irwin RW; Heber D; Go VL; Koeffler HP; Uskokovic MR; Harris DM. 2002. 1alpha,25-(OH)(2)-D(3) and its synthetic analogue decrease tumor load in the Apc(min) Mouse. Cancer Res 62(3):741-6. [PubMed: 11830528]  [MGI Ref ID J:74361]

Iinuma T; Homma S; Noda T; Kufe D; Ohno T; Toda G. 2004. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 113(9):1307-17. [PubMed: 15124022]  [MGI Ref ID J:90168]

Kawajiri H; Hsi LC; Kamitani H; Ikawa H; Geller M; Ward T; Eling TE; Glasgow WC. 2002. Arachidonic and linoleic acid metabolism in mouse intestinal tissue: evidence for novel lipoxygenase activity. Arch Biochem Biophys 398(1):51-60. [PubMed: 11811948]  [MGI Ref ID J:74371]

Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S. 2001. Suppression of intestinal polyps in msh2-deficient and non-msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 61(16):6131-6. [PubMed: 11507063]  [MGI Ref ID J:70902]

Lew JI; Guo Y; Kim RK; Vargish L; Michelassi F; Arenas RB. 2002. Reduction of Intestinal Neoplasia With Adenomatous Polyposis Coli Gene Replacement and COX-2 Inhibition Is Additive. J Gastrointest Surg 6(4):563-8. [PubMed: 12127122]  [MGI Ref ID J:77954]

Lustig B; Jerchow B; Sachs M; Weiler S; Pietsch T; Karsten U; van de Wetering M; Clevers H; Schlag PM; Birchmeier W; Behrens J. 2002. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22(4):1184-93. [PubMed: 11809809]  [MGI Ref ID J:74286]

Mabley JG; Pacher P; Bai P; Wallace R; Goonesekera S; Virag L; Southan GJ; Szabo C. 2004. Suppression of intestinal polyposis in Apcmin/+ mice by targeting the nitric oxide or poly(ADP-ribose) pathways. Mutat Res 548(1-2):107-16. [PubMed: 15063141]  [MGI Ref ID J:89155]

Mai V; Colbert LH; Berrigan D; Perkins SN; Pfeiffer R; Lavigne JA; Lanza E; Haines DC; Schatzkin A; Hursting SD. 2003. Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms. Cancer Res 63(8):1752-5. [PubMed: 12702556]  [MGI Ref ID J:82980]

Marten K; Bremer C; Khazaie K; Sameni M; Sloane B; Tung CH; Weissleder R. 2002. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122(2):406-14. [PubMed: 11832455]  [MGI Ref ID J:74358]

Mollersen L; Vikse R; Andreassen A; Steffensen IL; Mikalsen A; Paulsen JE; Alexander J. 2004. Adenomatous polyposis coli truncation mutations in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced intestinal tumours of multiple intestinal neoplasia mice. Mutat Res 557(1):29-40. [PubMed: 14706516]  [MGI Ref ID J:87470]

Mutanen M; Pajari AM; Oikarinen SI. 2000. Beef induces and rye bran prevents the formation of intestinal polyps in Apc(Min) mice: relation to beta-catenin and PKC isozymes. Carcinogenesis 21(6):1167-73. [PubMed: 10837006]  [MGI Ref ID J:62978]

Niho N; Takahashi M; Kitamura T; Shoji Y; Itoh M; Noda T; Sugimura T; Wakabayashi K. 2003. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 63(18):6090-5. [PubMed: 14522940]  [MGI Ref ID J:86036]

Oikannen SI; Pajari A; Mutanen M. 2000. Chemopreventive activity of hydroksymatairesinol in adenomatous polyposis colimultiple intestinal neoplasia (Apc)(Min) mice Cancer Lett 159(2):183-7. [PubMed: 10996730]  [MGI Ref ID J:64666]

Oikarinen S; Heinonen S; Karppinen S; Matto J; Adlercreutz H; Poutanen K; Mutanen M. 2003. Plasma enterolactone or intestinal Bifidobacterium levels do not explain adenoma formation in multiple intestinal neoplasia (Min) mice fed with two different types of rye-bran fractions. Br J Nutr 90(1):119-25. [PubMed: 12844383]  [MGI Ref ID J:85024]

Paoni NF; Feldman MW; Gutierrez LS; Ploplis VA; Castellino FJ. 2003. Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse. Physiol Genomics 15(3):228-35. [PubMed: 13130079]  [MGI Ref ID J:86113]

Paulsen JE; Alexander J. 2001. Growth stimulation of intestinal tumours in Apc(Min/+) mice by dietary L-methionine supplementation. Anticancer Res 21(5):3281-4. [PubMed: 11848484]  [MGI Ref ID J:75262]

Paulsen JE; Namork E; Steffensen IL; Eide TJ; Alexander J. 2000. Identification and quantification of aberrant crypt foci in the colon of Min mice--a murine model of familial adenomatous polyposis Scand J Gastroenterol 35(5):534-9. [PubMed: 10868458]  [MGI Ref ID J:62966]

Perkins S; Verschoyle RD; Hill K; Parveen I; Threadgill MD; Sharma RA; Williams ML; Steward WP; Gescher AJ. 2002. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 11(6):535-40. [PubMed: 12050094]  [MGI Ref ID J:77168]

Rao CV; Cooma I; Rodriguez JG; Simi B; El-Bayoumy K; Reddy BS. 2000. Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate. Carcinogenesis 21(4):617-21. [PubMed: 10753194]  [MGI Ref ID J:61783]

Reuter BK; Zhang XJ; Miller MJ. 2002. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2(1):19. [PubMed: 12171603]  [MGI Ref ID J:78510]

Roy HK; Karoski WJ; Ratashak A; Smyrk TC. 2001. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 downregulation. Br J Cancer 84(10):1412-6. [PubMed: 11355956]  [MGI Ref ID J:69899]

Schmelz EM; Roberts PC; Kustin EM; Lemonnier LA; Sullards MC; Dillehay DL; Merrill AH Jr. 2001. Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 61(18):6723-9. [PubMed: 11559543]  [MGI Ref ID J:71590]

Shailubhai K; Yu HH; Karunanandaa K; Wang JY; Eber SL; Wang Y; Joo NS; Kim HD; Miedema BW; Abbas SZ; Boddupalli SS; Currie MG; Forte LR. 2000. Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 60(18):5151-7. [PubMed: 11016642]  [MGI Ref ID J:64784]

Sibani S; Melnyk S; Pogribny IP; Wang W; Hiou-Tim F; Deng L; Trasler J; James SJ; Rozen R. 2002. Studies of methionine cycle intermediates (SAM, SAH), DNA methylation and the impact of folate deficiency on tumor numbers in Min mice. Carcinogenesis 23(1):61-5. [PubMed: 11756224]  [MGI Ref ID J:73559]

Silverman KA; Koratkar RA; Siracusa LD; Buchberg AM. 2003. Exclusion of Madh2, Madh4, and Madh7 as candidates for the modifier of Min 2 ( Mom2) locus. Mamm Genome 14(2):119-29. [PubMed: 12584607]  [MGI Ref ID J:81868]

Sohn KJ; Choi M; Song J; Chan S; Medline A; Gallinger S; Kim YI. 2003. Msh2 deficiency enhances somatic Apc and p53 mutations in Apc+/-Msh2-/- mice. Carcinogenesis 24(2):217-24. [PubMed: 12584170]  [MGI Ref ID J:79407]

Song J; Medline A; Mason JB; Gallinger S; Kim YI. 2000. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse Cancer Res 60(19):5434-40. [PubMed: 11034085]  [MGI Ref ID J:65027]

Steffensen IL; Schut HA; Paulsen JE; Andreassen A; Alexander J. 2001. Intestinal tumorigenesis in multiple intestinal neoplasia mice induced by the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine: perinatal susceptibility, regional variation, and correlation with DNA adducts. Cancer Res 61(24):8689-96. [PubMed: 11751386]  [MGI Ref ID J:73361]

Suckow MA; Gutierrez LS; Risatti CA; Wolter WR; Taylor RE; Pollard M; Navari RM; Castellino FJ; Paoni NF. 2004. The anti-ischemia agent ranolazine promotes the development of intestinal tumors in APC(Min/+) mice. Cancer Lett 209(2):165-9. [PubMed: 15159018]  [MGI Ref ID J:90679]

Suganuma M; Ohkura Y; Okabe S; Fujiki H. 2001. Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tumor formation in Min mice. J Cancer Res Clin Oncol 127(1):69-72. [PubMed: 11206275]  [MGI Ref ID J:67939]

Suzui M; Okuno M; Tanaka T; Nakagama H; Moriwaki H. 2002. Enhanced colon carcinogenesis induced by azoxymethane in min mice occurs via a mechanism independent of beta-catenin mutation. Cancer Lett 183(1):31-41. [PubMed: 12049812]  [MGI Ref ID J:77169]

Symolon H; Schmelz EM; Dillehay DL; Merrill AH Jr. 2004. Dietary Soy Sphingolipids Suppress Tumorigenesis and Gene Expression in 1,2-Dimethylhydrazine-Treated CF1 Mice and Apc(Min/+) Mice. J Nutr 134(5):1157-1161. [PubMed: 15113963]  [MGI Ref ID J:90172]

Trasler J; Deng L; Melnyk S; Pogribny I; Hiou-Tim F; Sibani S; Oakes C; Li E; James SJ; Rozen R. 2003. Impact of Dnmt1 deficiency, with and without low folate diets, on tumor numbers and DNA methylation in Min mice. Carcinogenesis 24(1):39-45. [PubMed: 12538347]  [MGI Ref ID J:81577]

Tucker J; Davis C; Kitchens M; Bunni M; Priest D; Spencer H; Berger F. 2002. Response to 5-fluorouracil chemotherapy is modified by dietary folic acid deficiency in Apc(Min/+) mice. Cancer Lett 187(1-2):153. [PubMed: 12359363]  [MGI Ref ID J:79692]

Wagenaar-Miller RA; Hanley G; Shattuck-Brandt R; DuBois RN; Bell RL; Matrisian LM; Morgan DW. 2003. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer 88(9):1445-52. [PubMed: 12778076]  [MGI Ref ID J:83488]

Wang D; Wang H; Shi Q; Katkuri S; Walhi W; Desvergne B; Das SK; Dey SK; DuBois RN. 2004. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6(3):285-95. [PubMed: 15380519]  [MGI Ref ID J:93551]

Weber GF; Bronson RT; Ilagan J; Cantor H; Schmits R; Mak TW. 2002. Absence of the CD44 gene prevents sarcoma metastasis. Cancer Res 62(8):2281-6. [PubMed: 11956084]  [MGI Ref ID J:76201]

Weyant MJ; Carothers AM; Dannenberg AJ; Bertagnolli MM. 2001. (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse. Cancer Res 61(1):118-25. [PubMed: 11196148]  [MGI Ref ID J:67060]

Weyant MJ; Carothers AM; Mahmoud NN; Bradlow HL; Remotti H; Bilinski RT; Bertagnolli MM. 2001. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res 61(6):2547-51. [PubMed: 11289129]  [MGI Ref ID J:68469]

Yamada T; Mori Y; Hayashi R; Takada M; Ino Y; Naishiro Y; Kondo T; Hirohashi S. 2003. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res 63(5):895-901. [PubMed: 12615699]  [MGI Ref ID J:82288]

Yamada Y; Hata K; Hirose Y; Hara A; Sugie S; Kuno T; Yoshimi N; Tanaka T; Mori H. 2002. Microadenomatous lesions involving loss of apc heterozygosity in the colon of adult apc(min/+) mice. Cancer Res 62(22):6367-70. [PubMed: 12438216]  [MGI Ref ID J:80301]

Yang K; Fan K; Kurihara N; Shinozaki H; Rigas B; Augenlicht L; Kopelovich L; Edelmann W; Kucherlapati R; Lipkin M. 2003. Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 24(3):605-11. [PubMed: 12663524]  [MGI Ref ID J:82832]

Yu CF; Whiteley L; Carryl O; Basson MD. 2001. Differential dietary effects on colonic and small bowel neoplasia in C57BL/6J Apc Min/+ mice. Dig Dis Sci 46(7):1367-80. [PubMed: 11478486]  [MGI Ref ID J:70920]

Ziegler CC; Rainwater L; Whelan J; McEntee MF. 2004. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 134(1):5-10. [PubMed: 14704285]  [MGI Ref ID J:88124]

ApcMin related

Ahn B; Ohshima H. 2001. Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res 61(23):8357-60. [PubMed: 11731407]  [MGI Ref ID J:73152]

Akporiaye ET; Bradley-Dunlop D; Gendler SJ; Mukherjee P; Madsen CS; Hahn T; Besselsen DG; Dial SM; Cui H; Trevor K. 2007. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine 25(39-40):6965-74. [PubMed: 17707958]  [MGI Ref ID J:128727]

Andreassen A; Mollersen L; Vikse R; Steffensen IL; Mikalsen A; Paulsen JE; Alexander J. 2002. One dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) induces tumours in Min/+ mice by truncation mutations or LOH in the Apc gene. Mutat Res 517(1-2):157-66. [PubMed: 12034317]  [MGI Ref ID J:77184]

Andreassen A; Vikse R; Mikalsen A; Adamovic T; Steffensen IL; Hjertholm H; Levan G; Alexander J. 2006. 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induces genetic changes in murine intestinal tumours and cells with Apc(Min) mutation. Mutat Res 604(1-2):60-70. [PubMed: 16574467]  [MGI Ref ID J:107714]

Andreassen A; Vikse R; Steffensen IL; Paulsen JE; Alexander J. 2001. Intestinal tumours induced by the food carcinogen 2-amino-1-methyl-6-phenylimidazo. Mutagenesis 16(4):309-15. [PubMed: 11420398]  [MGI Ref ID J:70642]

Arenas RB; Fichera A; Mok P; Blanco MC; Michelassi F. 1996. Introduction of human adenomatous polyposis coli gene into Min mice via cationic liposomes. Surgery 120(4):712-7. [PubMed: 8862382]  [MGI Ref ID J:36700]

Bacher JW; Abdel Megid WM; Kent-First MG; Halberg RB. 2005. Use of mononucleotide repeat markers for detection of microsatellite instability in mouse tumors. Mol Carcinog 44(4):285-92. [PubMed: 16240453]  [MGI Ref ID J:107080]

Backlund MG; Mann JR; Holla VR; Buchanan FG; Tai HH; Musiek ES; Milne GL; Katkuri S; DuBois RN. 2005. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 280(5):3217-23. [PubMed: 15542609]  [MGI Ref ID J:105183]

Baek SJ; Okazaki R; Lee SH; Martinez J; Kim JS; Yamaguchi K; Mishina Y; Martin DW; Shoieb A; McEntee MF; Eling TE. 2006. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131(5):1553-60. [PubMed: 17101328]  [MGI Ref ID J:120981]

Baker SM; Harris AC; Tsao JL; Flath TJ; Bronner CE; Gordon M ; Shibata D ; Liskay RM. 1998. Enhanced intestinal adenomatous polyp formation in Pms2-/-;Min mice. Cancer Res 58(6):1087-9. [PubMed: 9515784]  [MGI Ref ID J:46419]

Baltgalvis KA; Berger FG; Pena MM; Davis JM; Muga SJ; Carson JA. 2008. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 294(2):R393-401. [PubMed: 18056981]  [MGI Ref ID J:130429]

Barak Y; Liao D; He W; Ong ES; Nelson MC; Olefsky JM; Boland R; Evans RM. 2002. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci U S A 99(1):303-8. [PubMed: 11756685]  [MGI Ref ID J:73557]

Baran AA; Silverman KA; Zeskand J; Koratkar R; Palmer A; McCullen K; Curran WJ Jr; Edmonston TB; Siracusa LD; Buchberg AM. 2007. The modifier of Min 2 (Mom2) locus: embryonic lethality of a mutation in the Atp5a1 gene suggests a novel mechanism of polyp suppression. Genome Res 17(5):566-76. [PubMed: 17387143]  [MGI Ref ID J:122207]

Barbour K W; Davis T; White A; Baumann H; Berger F G. 2001. Haptoglobin, inflammation, and tumorigenesis in the MIN mouse. Redox Rep 6(6):366-8. [PubMed: 11865977]  [MGI Ref ID J:75249]

Barker N; van Es JH; Kuipers J; Kujala P; van den Born M; Cozijnsen M; Haegebarth A; Korving J; Begthel H; Peters PJ; Clevers H. 2007. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449(7165):1003-7. [PubMed: 17934449]  [MGI Ref ID J:127123]

Barnes CJ; Lee M. 1998. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 114(5):873-7. [PubMed: 9558273]  [MGI Ref ID J:48008]

Bashir O; FitzGerald AJ; Goodlad RA. 2004. Both suboptimal and elevated vitamin intake increase intestinal neoplasia and alter crypt fission in the ApcMin/+ mouse. Carcinogenesis 25(8):1507-15. [PubMed: 15016659]  [MGI Ref ID J:91525]

Bashir O; Fitzgerald AJ; Berlanga-Acosta J; Playford RJ; Goodlad RA. 2003. Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin Sci (Lond) 105(3):323-330. [PubMed: 12749762]  [MGI Ref ID J:84232]

Batlle E; Bacani J; Begthel H; Jonkeer S; Gregorieff A; van de Born M; Malats N; Sancho E; Boon E; Pawson T; Gallinger S; Pals S; Clevers H. 2005. EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045):1126-30. [PubMed: 15973414]  [MGI Ref ID J:99366]

Beazer-Barclay Y; Levy DB; Moser AR; Dove WF; Hamilton SR; Vogelstein B; Kinzler KW. 1996. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17(8):1757-60. [PubMed: 8761438]  [MGI Ref ID J:101582]

Bennett LM; McAllister KA; Ward T; Malphurs J; Collins NK; Seely JC; Davis BJ; Wiseman RW. 2001. Mammary tumor induction and premature ovarian failure in ApcMin mice are not enhanced by Brca2 deficiency. Toxicol Pathol 29(1):117-25. [PubMed: 11215675]  [MGI Ref ID J:67445]

Berger FG; Kramer DL; Porter CW. 2007. Polyamine metabolism and tumorigenesis in the Apc(Min/+) mouse. Biochem Soc Trans 35(Pt 2):336-9. [PubMed: 17371273]  [MGI Ref ID J:122673]

Bilger A; Shoemaker AR; Gould KA; Dove WF. 1996. Manipulation of the mouse germline in the study of Min-induced neoplasia. Semin Cancer Biol 7(5):249-60. [PubMed: 9110402]  [MGI Ref ID J:40100]

Bilger A; Sullivan R; Prunuske AJ; Clipson L; Drinkwater NR; Dove WF. 2008. Widespread hyperplasia induced by transgenic TGFalpha in ApcMin mice is associated with only regional effects on tumorigenesis. Carcinogenesis 29(9):1825-30. [PubMed: 18310091]  [MGI Ref ID J:139925]

Bjerknes M; Cheng H. 1999. Colossal crypts bordering colon adenomas in Apc(Min) mice express full-length Apc. Am J Pathol 154(6):1831-4. [PubMed: 10362808]  [MGI Ref ID J:55509]

Blanc V; Henderson JO; Newberry RD; Xie Y; Cho SJ; Newberry EP; Kennedy S; Rubin DC; Wang HL; Luo J; Davidson NO. 2007. Deletion of the AU-Rich RNA Binding Protein Apobec-1 Reduces Intestinal Tumor Burden in Apcmin Mice. Cancer Res 67(18):8565-73. [PubMed: 17875695]  [MGI Ref ID J:124876]

Bobe G; Wang B; Seeram NP; Nair MG; Bourquin LD. 2006. Dietary anthocyanin-rich tart cherry extract inhibits intestinal tumorigenesis in APC(Min) mice fed suboptimal levels of sulindac. J Agric Food Chem 54(25):9322-8. [PubMed: 17147414]  [MGI Ref ID J:121119]

Boivin GP; Washington K; Yang K; Ward JM; Pretlow TP; Russell R; Besselsen DG; Godfrey VL; Doetschman T; Dove WF; Pitot HC; Halberg RB; Itzkowitz SH; Groden J; Coffey RJ. 2003. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124(3):762-77. [PubMed: 12612914]  [MGI Ref ID J:82108]

Boolbol SK; Dannenberg AJ; Chadburn A; Martucci C; Guo XJ; Ramonetti JT; Abreu-Goris M; Newmark HL; Lipkin ML; DeCosse JJ; Bertagnolli MM. 1996. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56(11):2556-60. [PubMed: 8653697]  [MGI Ref ID J:33982]

Botrugno OA; Fayard E; Annicotte JS; Haby C; Brennan T; Wendling O; Tanaka T; Kodama T; Thomas W; Auwerx J; Schoonjans K. 2004. Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell 15(4):499-509. [PubMed: 15327767]  [MGI Ref ID J:92508]

Boudreau F; Lussier CR; Mongrain S; Darsigny M; Drouin JL; Doyon G; Suh ER; Beaulieu JF; Rivard N; Perreault N. 2007. Loss of cathepsin L activity promotes claudin-1 overexpression and intestinal neoplasia. FASEB J 21(14):3853-65. [PubMed: 17622569]  [MGI Ref ID J:134918]

Busquets L; Guillen H; DeFord ME; Suckow MA; Navari RM; Castellino FJ; Prorok M. 2006. Cathepsin E is a specific marker of dysplasia in APC mouse intestine. Tumour Biol 27(1):36-42. [PubMed: 16340248]  [MGI Ref ID J:106940]

Cai H; Al-Fayez M; Tunstall RG; Platton S; Greaves P; Steward WP; Gescher AJ. 2005. The rice bran constituent tricin potently inhibits cyclooxygenase enzymes and interferes with intestinal carcinogenesis in ApcMin mice. Mol Cancer Ther 4(9):1287-92. [PubMed: 16170019]  [MGI Ref ID J:103610]

Caldwell CM; Green RA; Kaplan KB. 2007. APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice. J Cell Biol 178(7):1109-20. [PubMed: 17893240]  [MGI Ref ID J:134792]

Carothers AM; Javid SH; Moran AE; Hunt DH; Redston M; Bertagnolli MM. 2006. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res 312(4):387-400. [PubMed: 16368433]  [MGI Ref ID J:105729]

Cebrat M; Strzadala L; Kisielow P. 2004. Wnt inhibitory factor-1: a candidate for a new player in tumorigenesis of intestinal epithelial cells. Cancer Lett 206(1):107-13. [PubMed: 15019166]  [MGI Ref ID J:88778]

Chadeneau C; LeCabellec M; LeMoullac B; Meflah K; Denis MG. 1996. Over-expression of a novel member of the immunoglobulin superfamily in Min mouse intestinal adenomas. Int J Cancer 68(6):817-21. [PubMed: 8980189]  [MGI Ref ID J:37448]

Chazaud C; Rossant J. 2006. Disruption of early proximodistal patterning and AVE formation in Apc mutants. Development 133(17):3379-87. [PubMed: 16887818]  [MGI Ref ID J:112232]

Chulada PC; Thompson MB; Mahler JF; Doyle CM; Gaul BW; Lee C; Tiano HF; Morham SG; Smithies O; Langenbach R. 2000. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60(17):4705-8. [PubMed: 10987272]  [MGI Ref ID J:64401]

Clarke AR; Cummings MC; Harrison DJ. 1995. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 11(9):1913-20. [PubMed: 7478622]  [MGI Ref ID J:29664]

Colbert LH; Davis JM; Essig DA; Ghaffar A; Mayer EP. 2000. Exercise and tumor development in a mouse predisposed to multiple intestinal adenomas. Med Sci Sports Exerc 32(10):1704-8. [PubMed: 11039641]  [MGI Ref ID J:65357]

Colbert LH; Mai V; Perkins SN; Berrigan D; Lavigne JA; Wimbrow HH; Alvord WG; Haines DC; Srinivas P; Hursting SD. 2003. Exercise and intestinal polyp development in APCMin mice. Med Sci Sports Exerc 35(10):1662-9. [PubMed: 14523302]  [MGI Ref ID J:101440]

Colbert LH; Mai V; Tooze JA; Perkins SN; Berrigan D; Hursting SD. 2006. Negative energy balance induced by voluntary wheel running inhibits polyp development in APCMin mice. Carcinogenesis 27(10):2103-7. [PubMed: 16699175]  [MGI Ref ID J:113355]

Cole AR; Ji H; Simpson RJ. 2000. Proteomic analysis of colonic crypts from normal, multiple intestinal neoplasia and p53-null mice: a comparison with colonic polyps Electrophoresis 21(9):1772-81. [PubMed: 10870964]  [MGI Ref ID J:62965]

Coletta PL; Muller AM; Jones EA; Muhl B; Holwell S; Clarke D; Meade JL; Cook GP; Hawcroft G; Ponchel F; Lam WK; MacLennan KA; Hull MA; Bonifer C; Markham AF. 2004. Lymphodepletion in the ApcMin/+ mouse model of intestinal tumorigenesis. Blood 103(3):1050-8. [PubMed: 14525778]  [MGI Ref ID J:87640]

Collett GP; Robson CN; Mathers JC; Campbell FC. 2001. Curcumin modifies Apc(min) apoptosis resistance and inhibits 2-amino 1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) induced tumour formation in Apc(min) mice. Carcinogenesis 22(5):821-5. [PubMed: 11323404]  [MGI Ref ID J:69213]

Colnot S; Niwa-Kawakita M; Hamard G; Godard C; Le Plenier S; Houbron C; Romagnolo B; Berrebi D; Giovannini M; Perret C. 2004. Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest 84(12):1619-30. [PubMed: 15502862]  [MGI Ref ID J:94108]

Cooper HS; Chang WC; Coudry R; Gary MA; Everley L; Spittle CS; Wang H; Litwin S; Clapper ML. 2005. Generation of a unique strain of multiple intestinal neoplasia (Apc(+/Min-FCCC)) mice with significantly increased numbers of colorectal adenomas. Mol Carcinog 44(1):31-41. [PubMed: 15937958]  [MGI Ref ID J:101103]

Cooper HS; Everley L; Chang WC; Pfeiffer G; Lee B; Murthy S; Clapper ML. 2001. The role of mutant apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121(6):1407-16. [PubMed: 11729120]  [MGI Ref ID J:72879]

Cormier RT; Dove WF. 2000. Dnmt1N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min 1(AKR) resistance allele. Cancer Res 60(14):3965-70. [PubMed: 10919675]  [MGI Ref ID J:63662]

Cormier RT; Hong KH; Halberg RB; Hawkins TL; Richardson P; Mulherkar R ; Dove WF ; Lander ES. 1997. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis [see comments] Nat Genet 17(1):88-91. [PubMed: 9288104]  [MGI Ref ID J:42722]

Corpet DE; Pierre F. 2003. Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 12(5):391-400. [PubMed: 12750232]  [MGI Ref ID J:84217]

Cortina C; Palomo-Ponce S; Iglesias M; Fernandez-Masip JL; Vivancos A; Whissell G; Huma M; Peiro N; Gallego L; Jonkheer S; Davy A; Lloreta J; Sancho E; Batlle E. 2007. EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells. Nat Genet 39(11):1376-83. [PubMed: 17906625]  [MGI Ref ID J:130035]

Czarnomska A; Krysiak E; Piskorowska J; Sitarz M; Pysniak K; Pilcik T; Demant P. 2003. Opposite effects of modifiers of the ApcMin mutation in intestine and mammary gland. Cancer Res 63(15):4533-7. [PubMed: 12907628]  [MGI Ref ID J:85697]

Dahlhoff M; Horst D; Gerhard M; Kolligs FT; Wolf E; Schneider MR. 2008. Betacellulin stimulates growth of the mouse intestinal epithelium and increases adenoma multiplicity in Apc(+/Min) mice. FEBS Lett 582(19):2911-5. [PubMed: 18656477]  [MGI Ref ID J:138998]

Dang DT; Bachman KE; Mahatan CS; Dang LH; Giardiello FM; Yang VW. 2000. Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients FEBS Lett 476(3):203-7. [PubMed: 10913614]  [MGI Ref ID J:63496]

Davis CD; Newman S. 2000. Inadequate dietary copper increases tumorigenesis in the min mouse Cancer Lett 159(1):57-62. [PubMed: 10974406]  [MGI Ref ID J:64669]

Davis CD; Zeng H; Finley JW. 2002. Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J Nutr 132(2):307-9. [PubMed: 11823596]  [MGI Ref ID J:74364]

Degg NL; Weil MM; Edwards A; Haines J; Coster M; Moody J; Ellender M; Cox R; Silver A. 2003. Adenoma multiplicity in irradiated apc(min) mice is modified by chromosome 16 segments from BALB/c. Cancer Res 63(10):2361-3. [PubMed: 12750251]  [MGI Ref ID J:83497]

Demidov ON; Timofeev O; Lwin HN; Kek C; Appella E; Bulavin DV. 2007. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 1(2):180-90. [PubMed: 18371349]  [MGI Ref ID J:139068]

Dietrich WF; Lander ES; Smith JS; Moser AR; Gould KA; Luongo C; Borenstein N; Dove W. 1993. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75(4):631-9. [PubMed: 8242739]  [MGI Ref ID J:15703]

Dinchuk JE; Focht RJ; Kelley JA; Henderson NL; Zolotarjova NI; Wynn R; Neff NT; Link J; Huber RM; Burn TC; Rupar MJ; Cunningham MR; Selling BH; Ma J; Stern AA; Hollis GF; Stein RB; Friedman PA. 2002. Absence of Post-translational Aspartyl beta -Hydroxylation of Epidermal Growth Factor Domains in Mice Leads to Developmental Defects and an Increased Incidence of Intestinal Neoplasia. J Biol Chem 277(15):12970-7. [PubMed: 11773073]  [MGI Ref ID J:75888]

Ding S; McEntee MF; Whelan J; Zemel M. 2007. Adiposity-related protection of intestinal tumorigenesis: interaction with dietary calcium. Nutr Cancer 58(2):153-61. [PubMed: 17640161]  [MGI Ref ID J:138109]

Dove WF; Clipson L; Gould KA; Luongo C; Marshall DJ; Moser AR; Newton MA; Jacoby RF. 1997. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res 57(5):812-4. [PubMed: 9041176]  [MGI Ref ID J:38777]

Dove WF; Cormier RT; Gould KA; Halberg RB; Merritt AJ; Newton MA; Shoemaker AR. 1998. The intestinal epithelium and its neoplasms: genetic, cellular and tissue interactions. Philos Trans R Soc Lond B Biol Sci 353(1370):915-23. [PubMed: 9684289]  [MGI Ref ID J:52642]

Dudley ME; Sundberg JP; Roopenian DC. 1996. Frequency and histological appearance of adenomas in multiple intestinal neoplasia mice are unaffected by severe combined immunodeficiency (scid) mutation. Int J Cancer 65(2):249-53. [PubMed: 8567125]  [MGI Ref ID J:31690]

Eads CA; Nickel AE; Laird PW. 2002. Complete Genetic Suppression of Polyp Formation and Reduction of CpG-Island Hypermethylation in Apc(Min/+) Dnmt1-Hypomorphic Mice. Cancer Res 62(5):1296-9. [PubMed: 11888894]  [MGI Ref ID J:75230]

Easwaran V; Lee SH; Inge L; Guo L; Goldbeck C; Garrett E; Wiesmann M; Garcia PD; Fuller JH; Chan V; Randazzo F; Gundel R; Warren RS; Escobedo J; Aukerman SL; Taylor RN; Fantl WJ. 2003. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Res 63(12):3145-53. [PubMed: 12810642]  [MGI Ref ID J:84505]

Elander N; Ungerback J; Olsson H; Uematsu S; Akira S; Soderkvist P. 2008. Genetic deletion of mPGES-1 accelerates intestinal tumorigenesis in APC(Min/+) mice. Biochem Biophys Res Commun 372(1):249-53. [PubMed: 18485889]  [MGI Ref ID J:136951]

Ellender M; Harrison JD; Edwards AA; Bouffler SD; Cox R. 2005. Direct single gene mutational events account for radiation-induced intestinal adenoma yields in apc(min/+) mice. Radiat Res 163(5):552-6. [PubMed: 15850417]  [MGI Ref ID J:98647]

Erdman SE; Sohn JJ; Rao VP; Nambiar PR; Ge Z; Fox JG; Schauer DB. 2005. CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res 65(10):3998-4004. [PubMed: 15899788]  [MGI Ref ID J:98546]

Erdman SH; Ignatenko NA; Powell MB; Blohm-Mangone KA; Holubec H; Guillen-Rodriguez JM; Gerner EW. 1999. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20(9):1709-13. [PubMed: 10469614]  [MGI Ref ID J:57289]

Erik Paulsen J; Steffensen IL; Loberg EM; Husoy T; Namork E; Alexander J. 2001. Qualitative and Quantitative Relationship between Dysplastic Aberrant Crypt Foci and Tumorigenesis in the Min/+ Mouse Colon. Cancer Res 61(13):5010-5. [PubMed: 11431334]  [MGI Ref ID J:70170]

Ernest S; Christensen B; Gilfix BM; Mamer OA; Hosack A; Rodier M; Colmenares C; McGrath J; Bale A; Balling R; Sankoff D; Rosenblatt DS; Nadeau JH. 2002. Genetic and molecular control of folate-homocysteine metabolism in mutant mice. Mamm Genome 13(5):259-67. [PubMed: 12016514]  [MGI Ref ID J:76559]

Fazeli A; Dickinson SL; Hermiston ML; Tighe RV; Steen RG; Small CG; Stoeckli ET; Keino-Masu K; Masu M; Rayburn H; Simons J; Bronson RT; Gordon JI; Tessier-Lavigne M; Weinberg RA. 1997. Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 386(6627):796-804. [PubMed: 9126737]  [MGI Ref ID J:39765]

Fein M; Peters JH; Baril N; McGarvey M; Chandrasoma P; Shibata D ; Laird PW ; Skinner KA. 1999. Loss of function of Trp53, but not Apc, leads to the development of esophageal adenocarcinoma in mice with jejunoesophageal reflux. J Surg Res 83(1):48-55. [PubMed: 10210642]  [MGI Ref ID J:55225]

Fingleton B; Carter KJ; Matrisian LM. 2007. Loss of functional Fas ligand enhances intestinal tumorigenesis in the Min mouse model. Cancer Res 67(10):4800-6. [PubMed: 17510409]  [MGI Ref ID J:121728]

Firestein R; Blander G; Michan S; Oberdoerffer P; Ogino S; Campbell J; Bhimavarapu A; Luikenhuis S; de Cabo R; Fuchs C; Hahn WC; Guarente LP; Sinclair DA. 2008. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 3(4):e2020. [PubMed: 18414679]  [MGI Ref ID J:134301]

Fodde R; Edelmann W; Yang K; van Leeuwen C; Carlson C; Renault B; Breukel C; Alt E; Lipkin M; Khan PM; Kucherlapati R. 1994. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 91(19):8969-73. [PubMed: 8090754]  [MGI Ref ID J:20443]

Frank H; Groger N; Diener M; Becker C; Braun T; Boettger T. 2008. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J Biol Chem 283(36):24729-37. [PubMed: 18562324]  [MGI Ref ID J:139883]

Gerner EW. 2007. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans 35(Pt 2):322-5. [PubMed: 17371270]  [MGI Ref ID J:122674]

Ghaleb AM; McConnell BB; Nandan MO; Katz JP; Kaestner KH; Yang VW. 2007. Haploinsufficiency of Kruppel-like factor 4 promotes adenomatous polyposis coli dependent intestinal tumorigenesis. Cancer Res 67(15):7147-54. [PubMed: 17671182]  [MGI Ref ID J:123915]

Gibson SL; Dai CY; Lee HW; DePinho RA; Gee MS; Lee WM; Furth EE; Brensinger C; Enders GH. 2003. Inhibition of colon tumor progression and angiogenesis by the ink4a/arf locus. Cancer Res 63(4):742-6. [PubMed: 12591718]  [MGI Ref ID J:81942]

Giroux V; Lemay F; Bernatchez G; Robitaille Y; Carrier JC. 2008. Estrogen receptor beta deficiency enhances small intestinal tumorigenesis in ApcMin/+ mice. Int J Cancer 123(2):303-11. [PubMed: 18464259]  [MGI Ref ID J:138676]

Goodlad RA; Ryan AJ; Wedge SR; Pyrah IT; Alferez D; Poulsom R; Smith NR; Mandir N; Watkins AJ; Wilkinson RW. 2006. Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis 27(10):2133-9. [PubMed: 16782971]  [MGI Ref ID J:113371]

Goss KH; Risinger MA; Kordich JJ; Sanz MM; Straughen JE; Slovek LE; Capobianco AJ; German J; Boivin GP; Groden J. 2002. Enhanced tumor formation in mice heterozygous for Blm mutation. Science 297(5589):2051-3. [PubMed: 12242442]  [MGI Ref ID J:79058]

Goss KJ; Brown PD; Matrisian LM. 1998. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78(5):629-35. [PubMed: 9808534]  [MGI Ref ID J:50603]

Gould KA; Dietrich WF; Borenstein N; Lander ES; Dove WF. 1996. Mom1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Genetics 144(4):1769-76. [PubMed: 8978062]  [MGI Ref ID J:37224]

Gould KA; Luongo C; Moser AR; McNeley MK; Borenstein N; Shedlovsky A; Dove WF; Hong K; Dietrich WF; Lander ES. 1996. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics 144(4):1777-85. [PubMed: 8978063]  [MGI Ref ID J:37223]

Gould TD; Gray NA; Manji HK. 2003. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice. Pharmacol Res 48(1):49-53. [PubMed: 12770514]  [MGI Ref ID J:84200]

Greiner JW; Zeytin H; Anver MR; Schlom J. 2002. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62(23):6944-51. [PubMed: 12460911]  [MGI Ref ID J:80324]

Guillen-Ahlers H; Buechler SA; Suckow MA; Castellino FJ; Ploplis VA. 2008. Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice. Carcinogenesis 29(7):1421-7. [PubMed: 18499699]  [MGI Ref ID J:139063]

Gupta RA; Wang D; Katkuri S; Wang H; Dey SK; DuBois RN. 2004. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10(3):245-7. [PubMed: 14758356]  [MGI Ref ID J:88127]

Gutierrez LS; Suckow M; Lawler J; Ploplis VA; Castellino FJ. 2003. Thrombospondin 1--a regulator of adenoma growth and carcinoma progression in the APC(Min/+) mouse model. Carcinogenesis 24(2):199-207. [PubMed: 12584168]  [MGI Ref ID J:79641]

Haigis KM; Dove WF. 2003. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity. Nat Genet 33(1):33-9. [PubMed: 12447373]  [MGI Ref ID J:80330]

Haigis KM; Hoff PD; White A; Shoemaker AR; Halberg RB; Dove WF. 2004. Tumor regionality in the mouse intestine reflects the mechanism of loss of Apc function. Proc Natl Acad Sci U S A 101(26):9769-73. [PubMed: 15210940]  [MGI Ref ID J:91411]

Haines J; Dunford R; Moody J; Ellender M; Cox R; Silver A. 2000. Loss of heterozygosity in spontaneous and x-ray-induced intestinal tumors arising in F1 hybrid min mice: evidence for sequential loss of apc(+) and dpc4 in tumor development Genes Chromosomes Cancer 28(4):387-94. [PubMed: 10862047]  [MGI Ref ID J:62971]

Haines J; Johnson V; Pack K; Suraweera N; Slijepcevic P; Cabuy E; Coster M; Ilyas M; Wilding J; Sieber O; Bodmer W; Tomlinson I; Silver A. 2005. Genetic basis of variation in adenoma multiplicity in ApcMin/+ Mom1S mice. Proc Natl Acad Sci U S A 102(8):2868-73. [PubMed: 15710876]  [MGI Ref ID J:96833]

Halberg RB; Chen X; Amos-Landgraf JM; White A; Rasmussen K; Clipson L; Pasch C; Sullivan R; Pitot HC; Dove WF. 2008. The pleiotropic phenotype of apc mutations in the mouse: allele specificity and effects of the genetic background. Genetics 180(1):601-9. [PubMed: 18723878]  [MGI Ref ID J:139675]

Halberg RB; Katzung DS; Hoff PD; Moser AR; Cole CE; Lubet RA; Donehower LA; Jacoby RF; Dove WF. 2000. Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci U S A 97(7):3461-6. [PubMed: 10716720]  [MGI Ref ID J:61200]

Halberg RB; Larsen MC; Elmergreen TL; Ko AY; Irving AA; Clipson L; Jefcoate CR. 2008. Cyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substrates. Cancer Res 68(18):7394-402. [PubMed: 18794127]  [MGI Ref ID J:141215]

Hance KW; Zeytin HE; Greiner JW. 2005. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res 576(1-2):132-54. [PubMed: 15888344]  [MGI Ref ID J:100615]

Hariri LP; Tumlinson AR; Besselsen DG; Utzinger U; Gerner EW; Barton JK. 2006. Endoscopic optical coherence tomography and laser-induced fluorescence spectroscopy in a murine colon cancer model. Lasers Surg Med 38(4):305-13. [PubMed: 16596657]  [MGI Ref ID J:115751]

Harman FS; Nicol CJ; Marin HE; Ward JM; Gonzalez FJ; Peters JM. 2004. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10(5):481-483. [PubMed: 15048110]  [MGI Ref ID J:90217]

Harper J; Burns JL; Foulstone EJ; Pignatelli M; Zaina S; Hassan AB. 2006. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 66(4):1940-8. [PubMed: 16488992]  [MGI Ref ID J:106661]

Hassan AB; Howell JA. 2000. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60(4):1070-6. [PubMed: 10706126]  [MGI Ref ID J:61216]

Hata K; Tanaka T; Kohno H; Suzuki R; Qiang SH; Yamada Y; Oyama T; Kuno T; Hirose Y; Hara A; Mori H. 2006. beta-Catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice. Cancer Lett 239(1):123-8. [PubMed: 16168560]  [MGI Ref ID J:114612]

Hensley HH; Chang WC; Clapper ML. 2004. Detection and volume determination of colonic tumors in Min mice by magnetic resonance micro-imaging. Magn Reson Med 52(3):524-9. [PubMed: 15334570]  [MGI Ref ID J:92889]

Hong KH; Bonventre JC; O'Leary E; Bonventre JV; Lander ES. 2001. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci U S A 98(7):3935-9. [PubMed: 11274413]  [MGI Ref ID J:68495]

Hu R; Khor TO; Shen G; Jeong WS; Hebbar V; Chen C; Xu C; Reddy B; Chada K; Kong AN. 2006. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27(10):2038-46. [PubMed: 16675473]  [MGI Ref ID J:113352]

Hu Y; Le Leu RK; Young GP. 2007. Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac. Cancer Lett 248(2):234-44. [PubMed: 16950562]  [MGI Ref ID J:120014]

Huang EH; Park JC; Appelman H; Weinberg AD; Banerjee M; Logsdon CD; Schmidt AM. 2006. Induction of inflammatory bowel disease accelerates adenoma formation in Min +/- mice. Surgery 139(6):782-8. [PubMed: 16782435]  [MGI Ref ID J:115828]

Huerta S; Irwin RW; Heber D; Go VL; Moatamed F; Huerta S; Ou C; Harris DM. 2003. Intestinal polyp formation in the Apcmin mouse: effects of levels of dietary calcium and altered vitamin D homeostasis. Dig Dis Sci 48(5):870-6. [PubMed: 12772782]  [MGI Ref ID J:84198]

Hulboy DL; Gautam S; Fingleton B; Matrisian LM. 2004. The influence of matrix metalloproteinase-7 on early mammary tumorigenesis in the multiple intestinal neoplasia mouse. Oncol Rep 12(1):13-7. [PubMed: 15201952]  [MGI Ref ID J:91647]

Hulit J; Wang C; Li Z; Albanese C; Rao M; Di Vizio D; Shah S; Byers SW; Mahmood R; Augenlicht LH; Russell R; Pestell RG. 2004. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. (Erratum: v 25(1):523) Mol Cell Biol 24(17):7598-611. [PubMed: 15314168]  [MGI Ref ID J:92787]

Hull MA; Booth JK; Tisbury A; Scott N; Bonifer C; Markham AF; Coletta PL. 1999. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br J Cancer 79(9-10):1399-405. [PubMed: 10188882]  [MGI Ref ID J:53622]

Hull MA; Faluyi OO; Ko CW; Holwell S; Scott DJ; Cuthbert RJ; Poulsom R; Goodlad R; Bonifer C; Markham AF; Coletta PL. 2006. Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis 27(3):382-91. [PubMed: 16219637]  [MGI Ref ID J:106584]

Husoy T; Abramsson-Zetterberg L; Olstorn HB; Paulsen JE; Alexander J. 2005. Adenomatous polyposis coli influences micronuclei induction by PhIP and acrylamide in mouse erythrocytes. Mutat Res 580(1-2):111-8. [PubMed: 15668113]  [MGI Ref ID J:95966]

Husoy T; Knutsen HK; Cruciani V; Olstorn HB; Mikalsen SO; Loberg EM; Alexander J. 2005. Connexin43 is overexpressed in Apc(Min/+)-mice adenomas and colocalises with COX-2 in myofibroblasts. Int J Cancer 116(3):351-8. [PubMed: 15800939]  [MGI Ref ID J:98957]

Ignatenko NA; Holubec H; Besselsen DG; Blohm-Mangone KA; Padilla-Torres JL; Nagle RB; de Alboranc IM; Guillen-R JM; Gerner EW. 2006. Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. Cancer Biol Ther 5(12):1658-64. [PubMed: 17106247]  [MGI Ref ID J:120790]

Jacoby RF; Cole CE; Hawk ET; Lubet RA. 2004. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127(3):838-44. [PubMed: 15362039]  [MGI Ref ID J:93405]

Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA. 2000. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos Cancer Res 60(7):1864-70. [PubMed: 10766173]  [MGI Ref ID J:61461]

Jacoby RF; Marshall DJ; Newton MA; Novakovic K; Tutsch K; Cole CE; Lubet RA; Kelloff GJ; Verma A; Moser AR; Dove WF. 1996. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 56(4):710-4. [PubMed: 8631000]  [MGI Ref ID J:79095]

Javid SH; Moran AE; Carothers AM; Redston M; Bertagnolli MM. 2005. Modulation of tumor formation and intestinal cell migration by estrogens in the Apc(Min/+) mouse model of colorectal cancer. Carcinogenesis 26(3):587-95. [PubMed: 15579483]  [MGI Ref ID J:96347]

Johnson L; Mercer K; Greenbaum D; Bronson RT; Crowley D; Tuveson DA; Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410(6832):1111-6. [PubMed: 11323676]  [MGI Ref ID J:68981]

Ju J; Hong J; Zhou JN; Pan Z; Bose M; Liao J; Yang GY; Liu YY; Hou Z; Lin Y; Ma J; Shih WJ; Carothers AM; Yang CS. 2005. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 65(22):10623-31. [PubMed: 16288056]  [MGI Ref ID J:103400]

Kakuni M; Morimura K; Wanibuchi H; Ogawa M; Min W; Hayashi S; Fukushima S. 2002. Food restriction inhibits the growth of intestinal polyps in multiple intestinal neoplasia mouse. Jpn J Cancer Res 93(3):236-41. [PubMed: 11927003]  [MGI Ref ID J:76214]

Karabinis ME; Larson D; Barlow C; Wynshaw-Boris A; Moser AR. 2001. Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice. Carcinogenesis 22(2):343-6. [PubMed: 11181458]  [MGI Ref ID J:67485]

Kemp CJ; Sun S; Gurley KE. 2001. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res 61(1):327-32. [PubMed: 11196181]  [MGI Ref ID J:67062]

Kennedy AR; Beazer-Barclay Y; Kinzler KW; Newberne PM. 1996. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res 56(4):679-82. [PubMed: 8630994]  [MGI Ref ID J:101589]

Kettunen HL; Kettunen AS; Rautonen NE. 2003. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 63(16):5136-42. [PubMed: 12941845]  [MGI Ref ID J:85142]

Khor TO; Cheung WK; Prawan A; Reddy BS; Kong AN. 2008. Chemoprevention of familial adenomatous polyposis in Apc(Min/+) mice by phenethyl isothiocyanate (PEITC). Mol Carcinog 47(5):321-5. [PubMed: 17932952]  [MGI Ref ID J:133548]

Kim DJ; Akiyama TE; Harman FS; Burns AM; Shan W; Ward JM; Kennett MJ; Gonzalez FJ; Peters JM. 2004. Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem 279(22):23719-27. [PubMed: 15033975]  [MGI Ref ID J:90337]

Klein IK; Ritland SR; Burgart LJ; Ziesmer SC; Roche PC; Gendler SJ; Karnes WE Jr. 2000. Adenoma-specific alterations of protein kinase C isozyme expression in Apc(MIN) mice Cancer Res 60(8):2077-80. [PubMed: 10786662]  [MGI Ref ID J:61731]

Knutsen HK; Olstorn HB; Paulsen JE; Husoy T; Goverud IL; Loberg EM; Kristiansen K; Alexander J. 2005. Increased levels of PPARbeta/delta and cyclin D1 in flat dysplastic ACF and adenomas in Apc(Min/+) mice. Anticancer Res 25(6B):3781-9. [PubMed: 16309164]  [MGI Ref ID J:106961]

Koh TJ; Bulitta CJ; Fleming JV; Dockray GJ; Varro A; Wang TC. 2000. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 106(4):533-9. [PubMed: 10953028]  [MGI Ref ID J:64625]

Kohlhepp RL; Hegge LF; Moser AR. 2001. The ROSA26 LacZ-neoR insertion confers resistance to mammary tumors in ApcMin/+ mice. Mamm Genome 12(8):606-11. [PubMed: 11471054]  [MGI Ref ID J:70825]

Kohlhepp RL; Hegge LF; Nett JE; Moser AR. 2000. ROSA26 mice carry a modifier of Min-induced mammary and intestinal tumor development. Mamm Genome 11(12):1058-62. [PubMed: 11130972]  [MGI Ref ID J:66060]

Kohno M; Momoi M; Oo ML; Paik JH; Lee YM; Venkataraman K; Ai Y; Ristimaki AP; Fyrst H; Sano H; Rosenberg D; Saba JD; Proia RL; Hla T. 2006. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 26(19):7211-23. [PubMed: 16980623]  [MGI Ref ID J:112972]

Kongkanuntn R; Bubb VJ; Sansom OJ; Wyllie AH; Harrison DJ; Clarke AR. 1999. Dysregulated expression of beta-catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice. Oncogene 18(51):7219-25. [PubMed: 10602475]  [MGI Ref ID J:59017]

Koratkar R; Pequignot E; Hauck WW; Siracusa LD. 2002. The CAST/Ei strain confers significant protection against Apc(Min) intestinal polyps, independent of the resistant modifier of Min 1 (Mom1) locus. Cancer Res 62(19):5413-7. [PubMed: 12359746]  [MGI Ref ID J:79690]

Koratkar R; Silverman KA; Pequignot E; Hauck WW; Buchberg AM; Siracusa LD. 2004. Analysis of reciprocal congenic lines reveals the C3H/HeJ genome to be highly resistant to Apc(Min) intestinal tumorigenesis. Genomics 84(5):844-52. [PubMed: 15475263]  [MGI Ref ID J:93365]

Kwong LN; Shedlovsky A; Biehl BS; Clipson L; Pasch CA; Dove WF. 2007. Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. Genetics 176(2):1237-44. [PubMed: 17435219]  [MGI Ref ID J:123865]

Laird PW; Jackson-Grusby L; Fazeli A; Dickinson SL; Jung WE; Li E; Weinberg RA; Jaenisch R. 1995. Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81(2):197-205. [PubMed: 7537636]  [MGI Ref ID J:25691]

Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S. 2001. Suppression of intestinal polyps in msh2-deficient and non-msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 61(16):6131-6. [PubMed: 11507063]  [MGI Ref ID J:70902]

Lambert JD; Kwon SJ; Ju J; Bose M; Lee MJ; Hong J; Hao X; Yang CS. 2008. Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate. Carcinogenesis 29(10):2019-24. [PubMed: 18684728]  [MGI Ref ID J:140207]

Law DJ; Labut EM; Merchant JL. 2006. Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia. Mamm Genome 17(10):999-1004. [PubMed: 17019648]  [MGI Ref ID J:115045]

Lawrance AK; Deng L; Brody LC; Finnell RH; Shane B; Rozen R. 2007. Genetic and nutritional deficiencies in folate metabolism influence tumorigenicity in Apcmin/+ mice. J Nutr Biochem 18(5):305-12. [PubMed: 16963246]  [MGI Ref ID J:121499]

Lee D; Pearsall RS; Das S; Dey SK; Godfrey VL; Threadgill DW. 2004. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 24(20):8907-16. [PubMed: 15456865]  [MGI Ref ID J:93327]

Lee J; Hargest R; Wasan H; Phillips RK. 2004. Liposome-mediated adenomatous polyposis coli gene therapy: a novel anti-adenoma strategy in multiple intestinal neoplasia mouse model. Dis Colon Rectum 47(12):2105-13. [PubMed: 15657662]  [MGI Ref ID J:96281]

Lefebvre AM; Chen I; Desreumaux P; Najib J; Fruchart JC; Geboes K; Briggs M; Heyman R; Auwerx J. 1998. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 4(9):1053-7. [PubMed: 9734399]  [MGI Ref ID J:49814]

Leitges M. 2007. Functional PKC in vivo analysis using deficient mouse models. Biochem Soc Trans 35(Pt 5):1018-20. [PubMed: 17956267]  [MGI Ref ID J:131178]

Levy DB; Smith KJ; Beazer-Barclay Y; Hamilton SR; Vogelstein B; Kinzler KW. 1994. Inactivation of both APC alleles in human and mouse tumors. Cancer Res 54(22):5953-8. [PubMed: 7954428]  [MGI Ref ID J:21856]

Li P; Schulz S; Bombonati A; Palazzo JP; Hyslop TM; Xu Y; Baran AA; Siracusa LD; Pitari GM; Waldman SA. 2007. Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. Gastroenterology 133(2):599-607. [PubMed: 17681179]  [MGI Ref ID J:126715]

Liddle FJ; Frank DA. 2008. STAT1 expression is not required for polyp formation in Min mice. Mol Carcinog 47(2):75-9. [PubMed: 17683066]  [MGI Ref ID J:129797]

Lim SK; Kim H; Lim SK; bin Ali A; Lim YK; Wang Y; Chong SM; Costantini F; Baumman H. 1998. Increased susceptibility in Hp knockout mice during acute hemolysis. Blood 92(6):1870-7. [PubMed: 9731043]  [MGI Ref ID J:49888]

Lin H; Yamada Y; Nguyen S; Linhart H; Jackson-Grusby L; Meissner A; Meletis K; Lo G; Jaenisch R. 2006. Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol 26(8):2976-83. [PubMed: 16581773]  [MGI Ref ID J:107386]

Linhart HG; Lin H; Yamada Y; Moran E; Steine EJ; Gokhale S; Lo G; Cantu E; Ehrich M; He T; Meissner A; Jaenisch R. 2007. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev 21(23):3110-22. [PubMed: 18056424]  [MGI Ref ID J:127808]

Lochner M; Peduto L; Cherrier M; Sawa S; Langa F; Varona R; Riethmacher D; Si-Tahar M; Di Santo JP; Eberl G. 2008. In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma